Norman Wong from Resverlogix has been replaced by Eric Campeau from Zenith Epigenetics on the agenda for next weeks "Discovery on Target: Targeting Epigenetic Readers and Chromatin Remodelers" meeting in Boston on 9/22 and 9/23.
9/22: 5:10 PM, Examining the Basic Actions of BET Proteins (one of the Interactive Breakout Discussion Groups)
Moderator: Eric Campeau, Ph.D., PMP, Director of Biology, Zenith Epigentics
- Actions of BET proteins and specifically BRD4 in mediating actions of Pol II that differentiates it from BRD2/3 activity
- Actions of BET proteins in selective vs. pan inhibition
- Actions of BET proteins in inflammation
9/23: 10:55 *Late Breaking Research* -
Preclinical Characterization of ZEN-3694, a Novel BET Bromodomain Inhibitor for the Treatment of Hematological and Solid Tumor Malignancies
Eric Campeau, Ph.D., PMP, Director of Biology, Zenith Epigenetics